Arriello hires Sam Tomlinson as VP of Drug Safety to develop and direct clinical and non-clinical PV services and solutions, and lead the company’s expanding multi-national PV team. The company is committed to hiring the best available talent to provide comprehensive safety services across the entire product lifecycle.
Dublin-based Arriello, a leading provider of integrated Regulatory Affairs, Pharmacovigilance (PV), and Auditing & QA solutions and services, has appointed Sam Tomlinson as the VP of Drug Safety. In this role, she will develop and direct clinical and non-clinical PV services and solutions and lead the company’s expanding multi-national PV team.
Arriello has a mission to provide tailored and innovative drug safety services to clients worldwide, and this latest high-profile appointment is a reflection of their ambition and commitment to hiring the best available talent. Tomlinson is a distinguished Pharmacovigilance professional with over 20 years of strategic and operational experience in global PV in both large pharma and small to medium-sized pharma organizations. She started her PV career working at Eli Lilly and has gone on to lead global PV teams working across a broad range of therapeutic areas, most recently with specialty pharma building safety and risk management systems.
Commenting on her appointment, Tomlinson said, “Arriello leads the field in providing innovative drug safety services to clients worldwide, so this is a great opportunity for me to contribute to the future of drug safety practices. I am looking forward to collaborating with colleagues and clients around the world as we continue to design and develop new PV solutions and services.”
Sam’s expertise spans across the product lifecycle from clinical trials, through post marketing and product discontinuation. She has also managed and supported numerous Health Authority inspections including EMA, FDA, MHRA, ANSM, Health Canada, HPRA, and AIFA. She has experience as an EU QPPV, and her appointment as VP of Drug Safety is expected to help Arriello provide more comprehensive safety services across the entire product lifecycle.
Arriello CEO and co-founder Alan White added, “Everyone at Arriello is delighted to welcome Sam on board as VP of Global Drug Safety. Her extensive experience in PV will help us provide more comprehensive safety services across the entire product lifecycle. It is a further reflection of our ambition and commitment to hiring the best available talent.”
Over the last year, Arriello has made several strategic senior appointments, including Pete Embley as Chief Regulatory Officer and Helen Lowe as Auditing & QA Director. The company provides risk management and compliance services to the pharmaceutical industry and has been making the development-to-market process faster, better, and smarter since 2008.
Arriello’s global services span the product life cycle from Clinical to post-submission Regulatory Affairs and Pharmacovigilance, Quality Assurance and Auditing, and innovative automation solutions. Headquartered in Ireland, with operations across Europe, the company consults and creates solutions across the EU, North America, LATAM, CIS, MENA, Asia, and South Africa. With their extensive global network, decades of combined experience, and ISO:9001 certification, Arriello is a trusted partner primarily to pharmaceutical and biotech companies. The valued clients rely on Arriello’s ability to deliver, however complex their requirements, through the company’s proven expertise, global coverage, and technology.